News
Multimedia
Publication
Conferences
Resources
Subscribe
Webcasts

Spotlight -

Downstream Processing|

Upstream Processing

Biopharma Insights-Thought Leadership from Marketers | Sponsored Content | Cygnus Technologies

Best Practices for Quantification of Residual Host Cell DNA with Real-time PCR

ByJenna Frame, PhD, Product Marketing Manager, Cygnus Technologies,Eric Bishop, Vice President, R&D, Cygnus Technologies

February 25th 2025

Antibody Affinity Extraction Outperforms Native Digestion as a Sample Preparation Method for LC-MS Detection of Host Cell Proteins in Drug Substances

ByAlla Zilberman, Vice President, Technical Marketing, Cygnus Technologies, LLC ,Darren Bertin,Stephen Stahlschmidt,Johanna Barnhill,Timothy Licknack,Jared Isaac

May 20th 2024

Predicting Retroviral Particle Clearance with MockV® Retrovirus-like Particles

ByAlla Zilberman, Vice President, Technical Marketing, Cygnus Technologies, LLC ,David Cetlin, Senior Director, MockV Products, Cygnus Technologies, LLC

February 17th 2023

AAE-MS™ as an Orthogonal Method in Host Cell Protein Analytics

ByAlla Zilberman, Vice President, Technical Marketing, Cygnus Technologies, LLC

May 17th 2022

HCP ELISA and HCP Antibody Coverage Analysis Methods

ByAlla Zilberman, Biopharma Insights Contributor, Vice President, Technical Marketing, Cygnus Technologies

April 5th 2021

Predicting Viral Clearance at Your Benchtop

ByDavid Cetlin, Biopharma Insights Contributor, Senior Director of R&D at Cygnus Technologies

July 27th 2020

Viral contamination is an inherent risk during the manufacture of therapeutic products such as antibodies, vaccines, viral vectors, and plasma derivates.

Trending on BioPharm International

Green Chemistry’s Role in Advancing US Chemical Innovation

Industry Outlook 2026: Biopharma Industry Confronts Skills Shortage with Strategic Automation (Part 2)

New $82 Million Biopharma Launch Targets Rare Disease Development With AI-Driven Strategy

How Biopharma Navigates the 2026 Economic Shift

GSK Acquisition of RAPT Signals Shift Toward Long-Acting Anti-IgE Therapies